Asthma Trials May Need More Pediatric Focus After GSK’s Mepolizumab, Breo Ellipta Woes
Executive Summary
Mepolizumab seems headed for approval in severe asthma – but only in adults; adolescent data in pivotal studies were promising, but too limited.